Bio-Techne Corporation (NASDAQ: TECH) today announced that Dr. Matt McManus, President of Bio-Techne's Diagnostics and ...
Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents, and diagnostic products, today ...
Combines chemiluminescence detection with dual-channel fluorescence in the near-infrared and infrared (NIR and IR) ranges for expanded multiplexing Enables up to 24 targets per sample and supports ...
Shares of Bio-Techne Corp. advanced 5.19% to $57.60 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index rising 0.77% to 6,890.07 and the ...
Aristotle Atlantic Partners, LLC, an investment advisor, released its “Large Cap Growth Strategy” first quarter 2025 investor letter. A copy of the letter can be downloaded here. The U.S. equity ...
Techne Corporation (Nasdaq: TECH), a global provider of life science tools, reagents and diagnostic products, visits the Nasdaq MarketSite in Times Square as part of the company’s 50th anniversary ...
StockStory.org on MSN
Medpace, Revvity, Azenta, Bio-Techne, and Oscar Health stocks trade down, what you need to know
What Happened? A number of stocks fell in the morning session after the Trump administration's announcement of new global tariffs reignited trade policy uncertainty. The move came swiftly after the ...
Bio-Techne TECH reported fourth-quarter fiscal 2025 adjusted earnings per share (EPS) of 53 cents, which surpassed the Zacks Consensus Estimate by 6%. The bottom line improved from the year-ago figure ...
Aristotle Atlantic Partners, LLC, an investment advisor, released its “Large Cap Growth Strategy” second quarter 2025 investor letter. A copy of the letter can be downloaded here. The US equity market ...
The DCF model implemented in this article suggests that Bio-Techne is overvalued by 34.53%. Bio-Techne has allocated significant financial resources to capex. Due to these resources, its revenues ...
Bio-Techne faces near-term growth headwinds from challenges in academic and biotech research funding, but retains strong leverage to growing spatial biology, proteomics, and cell/gene therapy research ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results